Our results demonstrated novel insights into the role of AMPK and HIF1α in HCC metabolic reprogramming and provided the therapeutic possibility through AMPK activation by our newly developed small molecule, SCT‐1015. This evidence concerns the gene HIF1A and hepatocellular carcinoma.